Hemogenyx Pharmaceuticals Plc (HOPHF)
OTC PINK OTC PINK Primary 
Hemogenyx Pharmaceuticals readies for phase I trial
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) confirmed it is in the final stages of opening a clinical site ahead of a phase I trial of its lead asset, HEMO-CAR-T, which is being developed to treat acute myeloid leukaemia (AML). In an update alongside interim results, it said that the world-renowned MD Anderson Center in Texas will treat the first patient.
Hemogenyx Pharmaceuticals passes crucial milestone ahead of phase I trial
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) has developed a clinical-grade assay to measure FLT3 protein levels in acute myeloid leukaemia (AML) cells. This test is essential for selecting patients for the upcoming phase I clinical trials of its HEMO-CAR-T treatment, which will begin soon at MD Anderson Cancer Center and later expand to the University of Pennsylvania Medical Center.
Hemogenyx adds new trial site; making progress on multiple fronts
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, said it has expanded its clinical trials for its lead asset, HEMO-CAR-T, adding a prestigious but unnamed US medical centre to its list of study sites. At the same time, clinical site setup is underway at the University of Pennsylvania and the new medical facility.
